UPDATE: Immuno-Oncology Combo works on Lung Cancer Regardless of PD-L1 Type

28/10/2016 - 2 minutes

AstraZeneca’s MedImmune (UK) has published phase Ib study results in The Lancet Oncology. These showed anti-tumour activity of a combination of investigational antibodies in patients with lung cancer.

medimmune_azn_nsclc_cancerThe trial considered patients undergoing treatment with durvalumab and tremelimumab, to see whether the drug combo  could act therapeuticaly against locally advanced or metastatic non-small cell lung cancer (NSCLC), irrespective of PD-L1 status.

Less than half of patients with NSCLC have tumours that are PD-L1 positive, leaving a significant unmet medical need in the PD-L1 negative patient population.

A cohort of 26 patients who were PD-L1 positive and PD-L1 negative status were treated (22% and 29% Objective response rate respectively) resulting in an overall 23% response rate for both types.

Durvalumab is an investigational human monoclonal antibody directed against programmed death ligand-1 (PD-L1), which blocks the interactions between PD-L1 and both PD-1 and B7.1 proteins.

Tremelimumab on the other hand inhibits the activity of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) to boost the immune response against cancer cells.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member